代谢相关脂肪性肝病患者回肠菌群特征研究*

doi:10.3969/j.issn.1672-5069.2025.03.009

Abstract

Abstract: Objective The aim of this study was to investigate characteristics of ileal microbiota in patients with metabolic associated fatty liver disease (MAFLD). Methods 54 patients with MAFLD and 18 individuals for physical examination were recruited in our hospital between January 2024 and November 2024, all underwent FibroScan scan for controlled attenuation parameter (CAP) and endoscopy with special device for ileal specimen collection. 16S rDNA sequencing was performed. Results Patients with MAFLD in our series were divided into mild, moderate and severe liver steatosis, with 18 cases in each; patients with MAFLD had an elevated Alpha diversity of ileal flora, with a gradual decrease in percentage of Turicibacter, a reduction in abundance of Lactobacillus and Veillonella, while having an increase in the abundance of Prevotella, Leptotrichia and Porphyromonas. Conclusion The diversity and abundance of ileal microbiota in patients with MAFLD change, which is related to the severity of the entity. The reduction of Turicibacter and the migration of oral colonizing bacteria might be characteristics of the ileal microbiota in patients with MAFLD.

Key words: Metabolic related fatty liver disease, Endoscopic sampling, Ileal flora, Turicibacter bacteria, Flora migration

Wei Taotao, Liu Tianye, Dai Gaozhong. Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(3): 354-357.

References

[1] 范建高, 杨荣. 全球非酒精性脂肪性肝病的流行趋势与疾病负担. 中华消化杂志, 2023, 43(4) : 248-252.
[2] 曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展. 实用肝脏病杂志, 2023, 26(6) : 769-772.
[3] 范建高, 李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志,2023,31(8):789-792.
[4] Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci, 2020, 21(15):5214.
[5] Collins S L, Stine J G, Bisanz J E, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol, 2023, 21(4) : 236-247.
[6] Tang Q, Jin G, Wang G, et al. Current sampling methods for gut microbiota: a call for more precise devices. Front Cell Infect Microbiol, 2020, 10: 151.
[7] 范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) . 实用肝脏病杂志, 2024, 27(4) : 494-510.
[8] Keam S J. Resmetirom: First approval. Drugs, 2024, 84(6) : 729-735.
[9] 薛峰, 魏来. 从代谢谈脂肪性肝病:疾病本源与新药终点再思考. 中华肝脏病杂志, 2023, 31(8) : 785-788.
[10] Gottlieb A, Canbay A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells, 2019, 8(11):532-539.
[11] Wei J, Luo J, Yang F, et al. Cultivated enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine. Gut Microbes, 2024, 16(1): 2351620.
[12] Kemis J H, Linke V, Barrett K L, et al. Genetic determinants of gut microbiota composition and bile acid profiles in mice. PLoS Genet, 2019, 15(8) : e1008073.
[13] Zhong Y, Nyman M, Fåk F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. Mol Nutr Food Res, 2015, 59(10) : 2066-2076.
[14] Chen Y, Xu C, Huang R, et al. Butyrate from pectin fermentation inhibits intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Nutr Biochem, 2018, 56: 175-182.
[15] Lynch J B, Gonzalez E L, Choy K, et al. Gut microbiota turicibacter strains differentially modify bile acids and host lipids. Nat Commun, 2023, 14(1) : 3669.
[16] Lau H C, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine, 2024, 100: 104952.
[17] Shanahan E R, Zhong L, Talley N J, et al. Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures. Aliment Pharmacol Ther, 2016, 43(11) : 1186-1196.
[18] Mottawea W, Butcher J, Li J, et al. The mucosal-luminal interface: an ideal sample to study the mucosa-associated microbiota and the intestinal microbial biogeography. Pediatr Res, 2019, 85(6) : 895-903.
[19] Cui J, Zheng X, Hou W, et al. The study of a remote-controlled gastrointestinal drug delivery and sampling system. Telemed J E Health, 2008, 14(7) : 715-719.
[20] Koziolek M, Grimm M, Becker D, et al. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the intellicap(©) system. J Pharm Sci, 2015, 104(9) : 2855-2863.

Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments